160 related articles for article (PubMed ID: 17261272)
1. CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing.
Chen HH; Wong YH; Geneviere AM; Fann MJ
Biochem Biophys Res Commun; 2007 Mar; 354(3):735-40. PubMed ID: 17261272
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation.
Chen HH; Wang YC; Fann MJ
Mol Cell Biol; 2006 Apr; 26(7):2736-45. PubMed ID: 16537916
[TBL] [Abstract][Full Text] [Related]
3. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
[TBL] [Abstract][Full Text] [Related]
4. CDK13, a Kinase Involved in Pre-mRNA Splicing, Is a Component of the Perinucleolar Compartment.
Even Y; Escande ML; Fayet C; Genevière AM
PLoS One; 2016; 11(2):e0149184. PubMed ID: 26886422
[TBL] [Abstract][Full Text] [Related]
5. Cdk12 and Cdk13 regulate axonal elongation through a common signaling pathway that modulates Cdk5 expression.
Chen HR; Lin GT; Huang CK; Fann MJ
Exp Neurol; 2014 Nov; 261():10-21. PubMed ID: 24999027
[TBL] [Abstract][Full Text] [Related]
6. Cyclin L is an RS domain protein involved in pre-mRNA splicing.
Dickinson LA; Edgar AJ; Ehley J; Gottesfeld JM
J Biol Chem; 2002 Jul; 277(28):25465-73. PubMed ID: 11980906
[TBL] [Abstract][Full Text] [Related]
7. CDC2L5, a Cdk-like kinase with RS domain, interacts with the ASF/SF2-associated protein p32 and affects splicing in vivo.
Even Y; Durieux S; Escande ML; Lozano JC; Peaucellier G; Weil D; Genevière AM
J Cell Biochem; 2006 Oct; 99(3):890-904. PubMed ID: 16721827
[TBL] [Abstract][Full Text] [Related]
8. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
Blazek D; Kohoutek J; Bartholomeeusen K; Johansen E; Hulinkova P; Luo Z; Cimermancic P; Ule J; Peterlin BM
Genes Dev; 2011 Oct; 25(20):2158-72. PubMed ID: 22012619
[TBL] [Abstract][Full Text] [Related]
9. CDK13, a new potential human immunodeficiency virus type 1 inhibitory factor regulating viral mRNA splicing.
Berro R; Pedati C; Kehn-Hall K; Wu W; Klase Z; Even Y; Genevière AM; Ammosova T; Nekhai S; Kashanchi F
J Virol; 2008 Jul; 82(14):7155-66. PubMed ID: 18480452
[TBL] [Abstract][Full Text] [Related]
10. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
[TBL] [Abstract][Full Text] [Related]
11. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
Zhang T; Kwiatkowski N; Olson CM; Dixon-Clarke SE; Abraham BJ; Greifenberg AK; Ficarro SB; Elkins JM; Liang Y; Hannett NM; Manz T; Hao M; Bartkowiak B; Greenleaf AL; Marto JA; Geyer M; Bullock AN; Young RA; Gray NS
Nat Chem Biol; 2016 Oct; 12(10):876-84. PubMed ID: 27571479
[TBL] [Abstract][Full Text] [Related]
12. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
Greenleaf AL
Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
[TBL] [Abstract][Full Text] [Related]
13. cdc2 kinase-mediated phosphorylation of splicing factor SF2/ASF.
Okamoto Y; Onogi H; Honda R; Yasuda H; Wakabayashi T; Nimura Y; Hagiwara M
Biochem Biophys Res Commun; 1998 Aug; 249(3):872-8. PubMed ID: 9731229
[TBL] [Abstract][Full Text] [Related]
14. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells.
Zhang G; Lan B; Zhang X; Lin M; Liu Y; Chen J; Guo F
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164450
[TBL] [Abstract][Full Text] [Related]
15. The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5'-splice site selection.
Dauksaite V; Akusjärvi G
Biochem J; 2004 Jul; 381(Pt 2):343-50. PubMed ID: 15068396
[TBL] [Abstract][Full Text] [Related]
16. Structural Mass Spectrometry Probes the Inhibitor-Induced Allosteric Activation of CDK12/CDK13-Cyclin K Dissociation.
Bai Y; Liu Z; Li Y; Zhao H; Lai C; Zhao S; Chen K; Luo C; Yang X; Wang F
J Am Chem Soc; 2023 May; 145(21):11477-11481. PubMed ID: 37207290
[TBL] [Abstract][Full Text] [Related]
17. The reversible inhibitor SR-4835 binds Cdk12/cyclin K in a noncanonical G-loop conformation.
Schmitz M; Kaltheuner IH; Anand K; Düster R; Moecking J; Monastyrskyi A; Duckett DR; Roush WR; Geyer M
J Biol Chem; 2024 Jan; 300(1):105501. PubMed ID: 38016516
[TBL] [Abstract][Full Text] [Related]
18. Do truncated cyclins contribute to aberrant cyclin expression in cancer?
Van Dross R; Browning PJ; Pelling JC
Cell Cycle; 2006 Mar; 5(5):472-7. PubMed ID: 16552186
[TBL] [Abstract][Full Text] [Related]
19. Structural and Functional Analysis of the Cdk13/Cyclin K Complex.
Greifenberg AK; Hönig D; Pilarova K; Düster R; Bartholomeeusen K; Bösken CA; Anand K; Blazek D; Geyer M
Cell Rep; 2016 Jan; 14(2):320-31. PubMed ID: 26748711
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the SR proteins ASF/SF2 and SC35 influences alternative splicing in vivo in diverse ways.
Wang J; Manley JL
RNA; 1995 May; 1(3):335-46. PubMed ID: 7489505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
